Drug Profile

MP 101 - MicrobiotiX

Alternative Names: MP-101 - MicrobiotiX

Latest Information Update: 08 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MicrobiotiX Co., Ltd.
Class Anti-infectives; Antibacterials; Bacteriophages
Mechanism of Action Cell wall degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Pneumonia

Most Recent Events

08 Dec 2025 Phase-I clinical trials in Pneumonia in South Korea (unspecified route) (MicrobiotiX Pipeline, December 2025)
05 Nov 2025 MicrobiotiX files for patent protection with WIPO for MP 101
27 Oct 2025 Microbiotix plans a phase I trial for Pneumonia in South Korea in 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com